Medicus Pharma Submits European Application for Prostate Cancer Drug Study
MT Newswires Live
Jun 08
Medicus Pharma (MDCX) submitted a clinical modification application with the European Union to support an upcoming phase 2b trial of its advanced prostate cancer treatment Teverelix, the drugmaker said Monday.
The phase 2b study aims to refine dosage options and analyze the safety, efficacy, and biological behavior of the therapy before starting registrational development, the company said.
The drug candidate targets prostate cancer patients who have an elevated risk for cardiovascular issues and require androgen deprivation therapy, Medicus Pharma said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.